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Prion diseases are fatal, progressive, neurodegenerative diseases caused by prion accu-
mulation in the brain and lymphoreticular system. Here we report that a single subcutaneous
injection of cellulose ethers (CEs), which are commonly used as inactive ingredients in
foods and pharmaceuticals, markedly prolonged the lives of mice and hamsters intracere-
brally or intraperitoneally infected with the 263K hamster prion. CEs provided sustained pro-
tection even when a single injection was given as long as one year before infection. These
effects were linked with persistent residues of CEs in various tissues. More effective CEs
had less macrophage uptake ratios and hydrophobic modification of CEs abolished the
effectiveness. CEs were significantly effective in other prion disease animal models; how-
ever, the effects were less remarkable than those observed in the 263K prion-infected ani-
mals. The genetic background of the animal model was suggested to influence the effects of
CEs. CEs did not modify prion protein expression but inhibited abnormal prion protein for-
mation in vitro and in prion-infected cells. Although the mechanism of CEs in vivo remains to
be solved, these findings suggest that they aid in elucidating disease susceptibility and pre-
venting prion diseases.
Author Summary
Prion diseases are progressive, fatal, neurodegenerative transmissible illnesses in humans
and animals caused by prion accumulation in the brain and lymphoreticular system.
Because they are prevalent in nature, with atypical forms continuing to emerge, prion dis-
eases are potential threats to both public health and the economy. However, there are no
effective methods to prevent these diseases. Here we report that cellulose ethers (CEs),
which are non-digestible water-soluble polysaccharides that are commonly used as inac-
tive ingredients in foods and pharmaceuticals, show prophylactic efficacy in prion-
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infected animals. CEs persist in various tissues and confer sustained preventive efficacy
for years, suggesting that they help to prevent prion diseases. Although the enteral absorp-
tion of CEs is limited, we found that a portion of the absorbed CEs influences disease pro-
gression. Therefore, CEs may be useful to assess disease susceptibility and prevent disease
occurrence.
Introduction
Prion diseases or transmissible spongiform encephalopathies are fatal neurodegenerative con-
ditions caused by prion accumulation in the brain and lymphoreticular system [1]. Creutz-
feldt–Jakob disease is the most common human prion disease that sporadically occurs mostly
in the elderly. The number of cases of human prion disease is very small at a few cases per mil-
lion persons, but the prevalence has been gradually increasing in accordance with the aging of
society [2]. Despite recent tremendous therapeutic developments [3–6], remedies or preven-
tive measures to inhibit disease progression or achieve significantly beneficial improvements
have not yet been established.
In animal prion diseases such as scrapie in sheep and bovine spongiform encephalopathy in
cattle, not only classical but also atypical, cases are known to sporadically occur [7]. In addi-
tion, cervine prion diseases such as chronic wasting disease are prevalent in domesticated as
well as wild animals [8]. These animal prion diseases have become potential threats to public
health and the economy. In particular, the issue of chronic wasting disease in wild animals is
serious because affected animals or prion-carriers are difficult to eliminate, prions of chronic
wasting disease are shed into excreta, and prions resist decomposition in soil and cadavers [8].
No means for preventing these animal diseases have been established, and development of pro-
phylactic measures such as vaccines has long been awaited. However, prions are not efficiently
eliminated by the immune system, which has stalled efforts to develop safe effective vaccines
[9–11].
In our early study on the development of a certain anti-prion compound, we noticed that
not only anti-prion compound-containing tablets but also placebo tablets prolonged the life-
span of peripherally prion-infected animals. Subsequent analysis of the tablet ingredients
revealed that cellulose ethers (CEs) modified disease progression of the prion-infected animals.
Here we report the anti-prion prophylactic efficacy of CEs, which have remarkable post- and
pre-infection protective effects of a single injection into prion-infected animals. These com-
pounds are non-digestible, non-ionic, water-soluble, polysaccharide derivatives commonly
used as inactive ingredients in foods, cosmetics, and pharmaceuticals. We also examined the
effectiveness of CEs when administered at various times post- or pre-infection in prion-
infected animals. In addition, we examined the pharmacokinetics, biological features, struc-
ture-activity relationships, and effectiveness of CEs in other prion disease models, and mecha-
nism of action. Finally the significance of the findings is discussed.
Results
Post-infection prophylactic effects
Hydroxypropyl methylcelluloses (HPMCs) were mainly used in this study because these com-
pounds are the most popularly utilized CEs. First, we analyzed the post-infection effectiveness
of HPMCs, which had similar contents of methyl modification [ca. 1.91 mol/anhydrous glu-
cose unit (AGU)] and hydroxypropyl modification (0.24 mol/AGU), but different viscosities.
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Chemical summaries and cumulative molar masses of molecular weight distribution of
HPMCs are shown in Fig 1a. It is obvious that depending on the viscosity, each HPMC had a
distinct molecular weight distribution of polymers with certain ranges of molecular sizes.
Because it is expected that macromolecules are not delivered from the blood to the brain
parenchyma through the blood–brain barrier, HPMCs were continuously infused into the
cerebral ventricle to bypass the blood–brain barrier, as described in a previous study on pento-
san polysulfate [12]. A 4-week continuous intracerebroventricular infusion (150 μg/day) of
HPMC samples when given 3 days post-infection (dpi) demonstrated remarkable extension of
survival times in Tg7 mice expressing hamster prion protein (PrP) [13–15] intracerebrally
infected with the hamster-adapted 263K prion [16]. Although two of the most viscous HPMC
samples could not be tested because of difficulty in handling the solution, the most effective
was 60SH-50, which extended the median survival time by about 4-fold (62 days! 238 days),
as compared to the vehicle control (Fig 1b).
On the other hand, unlike the case of previously reported macromolecules, such as pento-
san polysulfate [12], it was interesting that a single subcutaneous injection (4 g/kg body
weight) of HPMCs when given immediately after infection, demonstrated remarkable exten-
sion of survival times in Tg7 mice intracerebrally infected with the 263K prion. The most effec-
tive was also 60SH-50, which extended the median survival time by about 3-fold (48 days!
155.5 days), as compared to the vehicle control (Fig 1c).
When the median survival time (% of vehicle control) of HPMC-treated animals was plot-
ted against HPMC viscosity, efficacy was obviously related to viscosity. The efficacy–viscosity
relationships were bell-shaped, and an HPMC with a viscosity of approximately 100 mPa•s in
a 2% solution at 20˚C (equivalent to a 140-glucose-unit size) was most effective (Fig 1d).
Meanwhile, CEs as short as hexamers were still effective when administered into the cerebral
ventricle, although the effectiveness was not as remarkable as with large-sized CEs (S1 Fig).
The relationship between dosage and effectiveness revealed that efficacy was dependent on
dosage by either single subcutaneous injection or 4-week continuous intracerebroventricular
infusion (S2 Fig). Next, we determined whether variations in methyl or hydroxypropyl modifi-
cation had any effect on the efficacy of CEs with similar viscosities and found that efficacy was
not associated with the variations conferred by methyl or hydroxypropyl modifications (S3
Fig). In addition, we investigated whether contaminated materials had any effect on the effi-
cacy of CEs and found that efficacy was not associated with contaminant removal by activated
carbon treatment (S4 Fig). Although age [17] and sex [18,19] are known to affect the incuba-
tion times of prion-infected rodents at some instances, but the observed CE efficacy was simi-
lar in animals irrespective of these variables (S5 Fig).
Post-infection prophylactic effects in peripheral infection
A single injection of a representative HPMC, TC-5RW, into either the peritoneal cavity or the
tail vein demonstrated considerable efficacy in intracerebrally infected animals (S6a Fig).
However, daily oral administration of TC-5RW to intracerebrally infected animals was not
effective, even if it was started before they contracted the infection (S6b Fig). This result may
be due to the poor intestinal absorption of CEs [20].
On the other hand, in the case of peripheral infection such as intraperitoneal infection, CE
efficacy was enhanced, as compared to that of intracerebral infection. For instance, daily oral
administration of TC-5RW, which was ineffective against intracerebral infection, was remark-
ably effective, as continuous treatment with a diet containing 15% TC-5RW from 7 dpi
extended the median survival times of animals by about 3-fold (98 days! 296 days) (Fig 2a).
A single subcutaneous injection of TC-5RW (4 g/kg body weight) at 3 dpi extended the
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Fig 1. Post-infection prophylactic effects of CEs in intracerebral infection. (a) Chemical summary and
cumulative molar mass of molecular weight distribution of HPMCs used in the study. Molecular weight distribution was
analyzed by gel permeation chromatography (GPC) and dynamic light scattering of a 1% aqueous solution. AGU,
anhydroglucose units. (b) Survival of Tg7 mice intracerebrally infected with the 263K prion and treated with HPMCs by
a 4-week continuous intracerebroventricular infusion (150 μg/day) from 3 dpi. The log-rank test was used for survival
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median survival times of animals by about 6.7-fold (97 days! 651.5 days) (Fig 2b). The results
suggest that even a small amount of CE absorbed through the intestinal tract is effective over a
long period of time in case of peripheral infection, although absorption of CEs in the intestinal
tract is reportedly very limited when orally administered [20].
Post-symptomatic therapeutic effects
Because symptom onset in Tg7 mice was not clearly determined, Syrian hamsters were used.
Syrian hamsters infected with the 263K prion showed ataxia or unstable gait as an initial obvi-
ous disease sign at approximately 60 dpi. Thus, we examined the effectiveness of TC-5RW
given in pre-symptomatic or post-symptomatic disease stages. Similar to that of previously
reported anti-prion materials [12,21], the efficacy of CEs decreased with the delay of post-
infection timing of injection (Fig 3). A single administration of TC-5RW at an early
analyses. (c) Survival of Tg7 mice intracerebrally infected with the 263K prion and treated with HPMCs by a single
subcutaneous injection (4 g/kg body weight) at 0 dpi. The log-rank test was used for survival analyses. (d)
Relationship between HPMC viscosity and survival time of animals treated post-infection. Medians and quartiles of
the data of (b) and (c) are plotted. *P < 0.05; **P < 0.01; ***P < 0.005; log-rank test.
doi:10.1371/journal.ppat.1006045.g001
Fig 2. Prophylactic effects in intraperitoneal infection. (a) Survival of intraperitoneally prion-infected Tg7
mice treated with TC-5RW in a 15% TC-5RW-containing diet from 7 dpi to akinetic terminal disease. (b) Survival
of intraperitoneally prion-infected Tg7 mice treated with TC-5RW by a single subcutaneous injection (4 g/kg
body weight) at 3 dpi.
doi:10.1371/journal.ppat.1006045.g002
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symptomatic stage (65 dpi) although significantly effective, had a very limited effect on extend-
ing the survival.
Pre-infection prophylactic effects
Because the effectiveness of a single post-infection CE administration continued over a long
period, we examined the effectiveness of a single CE administration given months before infec-
tion and found that HPMCs given in a single subcutaneous injection prior to infection were
still clearly effective. HPMCs given 6 or 12 months prior to infection were slightly less effective
than, or as effective as, those given immediately after infection; even HPMCs given 19 months
before infection were still markedly effective (Fig 4a).
When the median survival time (% of vehicle control) of HPMC-treated animals was plot-
ted against the administration timing, efficacy tended to gradually decrease according to the
pre-infection interval (Fig 4b). However, there was no significant difference in median survival
times between the immediate post-infection intervention group and the 12-month pre-infec-
tion intervention group injected with 60SH-50 or 60SH-400. The most potent HPMC in the
12-month pre-infection intervention was slightly more viscous than the most potent HPMC in
the post-infection intervention (Figs 1d and 4c).
Pre-infection prophylactic effects of CEs were also observed in Syrian hamsters (S7 Fig). By
intraperitoneal infection, 60SH-50 or 60SH-400 extended the survival times of animals treated
at the 0-month pre-infection by about 3.8-fold (233 days! about 890 days) and that of ani-
mals treated at the 13-month pre-infection by about 2.0- to 2.3-fold (195 days! 398 ~ 449
days). Therefore, it is obvious that even a single administration of CEs not only around the
time of infection, but also as long as one year prior to infection, effectively extended the sur-
vival times of prion-infected animals.
Pharmacokinetics of subcutaneously injected CE
To elucidate the mechanism of action of CEs, pharmacokinetics of subcutaneously injected
radiolabeled TC-5RW were investigated in Tg7 mice. Immediately after injection, radiolabeled
TC-5RW was taken up into the blood (S8a Fig) and excreted in the urine and feces at a rate of
70% of the initial dose within 3 days. Thereafter, it was excreted considerably more slowly,
with 20% of the initial dose remaining in the body 2 weeks post-injection (S8b Fig). GPC
Fig 3. Post-symptomatic therapeutic effects. Survival analysis was performed in Syrian hamsters intracerebrally infected with
the 263K prion and treated with a single subcutaneous injection (4 g/kg body weight) of TC-5RW at an early post-infection stage (8
dpi), a pre-symptomatic stage (50 dpi), or a post-symptomatic stage (65 dpi). A plot of medians and quartiles of the survival times is
also shown. *P < 0.05; **P < 0.01; ***P < 0.005; log-rank test.
doi:10.1371/journal.ppat.1006045.g003
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Fig 4. Pre-infection prophylactic effects in intracerebral infection. (a) Survival of intracerebrally 263K
prion-infected Tg7 mice treated with HPMCs. A single subcutaneous injection (4 g/kg body weight) was given
at 6, 12, or 19 months before infection. (b) Relationship between pretreatment timing and survival time of
animals treated with HPMCs. Medians and quartiles from the data of representative HPMCs in (a) and Fig 1c
are plotted. *P < 0.05; **P < 0.01; ***P < 0.005; log-rank test. (c) Relationship between HPMC viscosity and
Cellulose Ethers Provide Sustained Protection against Prion Diseases
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analysis indicated that smaller-sized molecules of TC-5RW were preferentially excreted in the
urine and feces, and larger-sized molecules remained in the plasma (S8c Fig).
Next, long-term pharmacokinetics and distribution were investigated in Tg7 mice given a
single subcutaneous dose of radiolabeled TC-5RW. Radiolabeled TC-5RW was distributed in
various tissues for long periods, but a little was found in the brain parenchyma, where prions
accumulate and cause neurodegeneration (Fig 5a and 5b). Even after 6 months, amounts up to
a few percent of the injected dose per gram of tissue or fluid were observed in various body
parts, such as the adrenal cortex, choroid plexus, mandibular gland, thyroid gland, lymph,
spleen, and skin, whereas less than 0.02 percent of the injected dose per gram of tissue (equiva-
lent to ~10 μg/g tissue) was observed in the brain parenchyma. The elimination half-life of
TC-5RW in these tissues was 50–350 days (Fig 5c) and longest elimination half-life periods
were observed in the skeletal muscle, adrenal cortex, brain, and testis. GPC analysis revealed
that larger portions of administered TC-5RW remained in tissues (Fig 5d). Consequently, a
persistent residue of CE in the body is linked to long-lasting effects.
Macrophage uptake analysis
Because CEs have been recognized to be biologically inactive macromolecules, we speculated
that macrophages might be involved in the degradation and excretion of CEs administered in
the body. Thus, we investigated macrophage uptake of CEs using fluorescein–labeled HPMCs
and peritoneal macrophages of Tg7 mice and found that macrophage uptake ratios of HPMCs
differed from each other and were independent of viscosity (Fig 6a). When compared with the
data of the median survival times (% of vehicle control) of Tg7 mice treated with a single sub-
cutaneous dose of HPMCs, the macrophage uptake ratio was inversely correlated, particularly
with the survival time of 12-month pre-infection intervention, rather than that of the immedi-
ate post-infection intervention (Fig 6b). Therefore, more effective HPMCs in pre-infection
protection were phagocytized to a lesser extent by macrophages.
Structure–activity study
As a representative CE compound, methyl cellulose SM-4 was used for structure–activity stud-
ies. The chemical properties of tested compounds are shown in Fig 7a. The results of survival
analysis of Tg7 mice treated with each compound are shown in Fig 7b. Comparison of SMR vs.
SM-4 and SMR-HP vs. SMOx-HP indicated that a reduced modification of the reducing end
produced better effects. Diethylaminoethyl modification (SMR-DEAE) produced the most
excellent effects; carboxymethyl modification (SMR-CM) produced similar effects as hydroxy-
propyl modification (SMR-HP). In contrast to these hydrophilic modifications, hydrophobic
modifications with a propyl group (SMR-PR and SMR-PR-HB) were much less effective than
unmodified SMR. Further propyl group modification (SMR-PR-HB) was less effective than
less modification (SMR-PR). These results suggest that the hydrophilicity of the CEs contrib-
utes to the effectiveness.
Hydroxypropyl and methyl ether compounds with sugar backbones other than cellulose
were also analyzed in intracerebrally prion-infected Tg7 mice by a similar manner as per-
formed with CEs. Tested sugar structures included dextran, dextrin, pullulan, starch, chitin,
chitosan, and cyclodextrin. These polysaccharide ethers were ineffective (S1 Table), suggesting
that the cellulose backbone is essential for effective protection against prion diseases.
survival time of animals treated 12 or 19 months before infection. Medians and quartiles from the data of (a)
are plotted. *P < 0.05; **P < 0.01; ***P < 0.005; log-rank test.
doi:10.1371/journal.ppat.1006045.g004
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Fig 5. Long-term pharmacokinetics of subcutaneously injected 14C-TC-5RW. (a) Radioluminograms of Tg7
mice at 0.5, 3, or 6 months after a single subcutaneous injection of 14C-TC-5RW (2 g/kg body weight) (n = 1 for
each time point). (b) Temporal profile of 14C-TC-5RW radioactivity levels in each tissue of Tg7 mice given a single
subcutaneous 14C-TC-5RW injection. Radioactive signals in (a) were analyzed in technical triplicates, and the
mean and standard deviation are presented. (c) Elimination half-life of 14C-TC-5RW in each tissue of Tg7 mice
Cellulose Ethers Provide Sustained Protection against Prion Diseases
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CE efficacies in other prion disease animal models
The effects of CEs were also investigated in C57BL/6 mice intracerebrally infected with
mouse-adapted prion strains (RML scrapie prion and Fukuoka-1 human prion disease prion
in Fig 8, and 22L scrapie prion in S9a Fig). The effects of CEs were significantly observed in all
of the disease animal models, but were less remarkable than those observed in the 263K prion-
infected Tg7 mice. Because it is inferable that animals with shorter incubation periods, such as
given a single subcutaneous 14C-TC-5RW injection. This half-life was calculated from the data presented in (b). (d)
GPC profiles of 14C-TC-5RW radioactivity extracted from representative tissues of Tg7 mice 8 months after a single
subcutaneous 14C-TC-5RW injection (2 g/kg body weight). The profile of 14C-TC-5RW used for the study is shown
at the bottom.
doi:10.1371/journal.ppat.1006045.g005
Fig 6. Macrophage uptake analysis. (a) HPMC macrophage uptake ratio. This represents the percentage of the HPMC
amount of macrophage lysate vs. the amount added into the culture medium. The mean and standard deviation of triplicate
experiments are shown. (b) Analysis of the linear correlation between the macrophage uptake ratio and prophylactic efficacy of
HPMCs. Survival times of Tg7 mice treated with HPMCs immediately post-infection or treated 12 months prior to infection were
obtained from Figs 1c and 4a. Statistical correlations were identified using the Pearson’s correlation coefficient.
doi:10.1371/journal.ppat.1006045.g006
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Tg7 mice and Syrian hamsters, might show more remarkable CE effects than animals with lon-
ger incubation periods, we examined the effects of CEs in Tga20 mice, which have substantially
shorter incubation periods to mouse-adapted prion strains [22]. The effects of CEs in Tga20
mice were significant but less remarkable (S9b Fig).
Therefore, prion disease animal models influenced the effects of CEs, and prion strain-asso-
ciated factors or animal genetic backgrounds might contribute to the variation in CE efficacy.
One example of the influence of the animal genetic background was demonstrated in the com-
parison between ddY and ICR mice. Both mice are outbred strains similarly used in drug tox-
icity and pharmacokinetic studies, but obvious differences in CE efficacy were observed
between these mice (S10 Fig).
Effects on PrP expression and conversion
In prion diseases, normal PrP (PrPC) is conformationally converted to an abnormal protease-
resistant PrP (PrPSc) as the main component of the prion [1]. However, administration of CEs
Fig 7. Structure–activity study of CEs. (a)Chemical summary of SM-4 derivatives tested in the study. (b)
Survival of intracerebrally 263K prion-infected Tg7 mice treated with SM-4 derivatives. A single subcutaneous
injection (2 g/kg body weight) was given at 1 dpi.
doi:10.1371/journal.ppat.1006045.g007
Cellulose Ethers Provide Sustained Protection against Prion Diseases
PLOS Pathogens | DOI:10.1371/journal.ppat.1006045 December 14, 2016 11 / 23
did not modify the protein or gene expression level of PrP in the brain or spleen (Fig 9a and
9b). On the other hand, administration of CEs inhibited 263K prion amplification in the pro-
tein misfolding cyclic amplification reaction, which is a method to amplify PrPSc in vitro [23],
whereas a control compound, hydroxypropyl methyl dextran (70 kDa), did not inhibit amplifi-
cation (Fig 9c). Similarly, in persistently RML prion-infected cells [24], CEs inhibited PrPSc
formation in accordance with their in-vivo potencies, although higher concentrations of CEs
were needed (Fig 9d). CE administration did not affect the expression levels of total PrPC or
cell surface PrPC of the cells (Fig 9e and 9f). These results suggest that CEs inhibit PrPC–PrPSc
conversion without affecting PrPC metabolism.
Discussion
CEs as new anti-prion compounds
The results of the present study revealed that CEs, as new types of anti-prion compounds, can
effectively extend the life span of animals infected with prion not only peripherally but also
intracerebrally, even though CEs are macromolecules that are hardly capable of reaching the
brain parenchyma. CEs share no similarities in their structures or chemical properties with
previously reported anti-prion polymers, such as sulfated glycans [25,26], polyamines [27–31],
and cationic dendrimers [32–35]. Unlike these anionic and cationic polymers, CEs are non-
ionic but hydrophilic.
Fig 8. CE efficacies in other prion disease animal models. Survival analysis of C57BL/6 mice
intracerebrally infected with the RML prion or Fukuoka-1 prion was performed. The mice were treated with a
single subcutaneous injection of CEs at 4 g/kg body weight immediately after infection.
doi:10.1371/journal.ppat.1006045.g008
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Fig 9. CE effects on PrP expression and PrPSc formation. (a) Immunoblotting of PrPC in the brain and
spleen from Tg7 mice treated with TC-5RW (4 g/kg body weight) or vehicle at the designated time points
(n = 3 for each time point). Molecular size markers on the right indicate sizes in kDa. The mean and standard
deviation are shown in each bar graph. (b) PrP mRNA expression level in the brain and spleen from Tg7 mice
treated with TC-5RW (4 g/kg body weight) or vehicle at designated time points. The mean and standard
deviation (n = 3 for each time point) are shown. (c) Immunoblotting of protease-resistant PrPSc in the protein
Cellulose Ethers Provide Sustained Protection against Prion Diseases
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The long-lasting efficacy of CEs is an astonishing, distinct feature from any other com-
pounds previously reported [3–6,36–38]; a single post-infection subcutaneous injection of CEs
extended the life spans of peripherally infected mice nearly to natural life spans and extended
the life spans of intracerebrally infected mice by 2–3 fold. More astonishing is the pre-exposure
prophylactic effects of CEs, as no significant difference in efficacy was observed in the most
effective CE administered at an immediate post-infection or at one year pre-infection. No
other compounds or biological materials exogenously administered have been reported to
achieve these levels of post-infection and pre-infection prophylactic effects in peripherally or
intracerebrally prion-infected animals.
Biological and chemical properties of effective CEs
CE molecules were distributed throughout the body within days after a single subcutaneous
injection, and larger-sized portions of the molecules were retained in the body for months.
The ability of CE residues to remain in the body is associated with the long-lasting protective
effects of CEs. Chemically, the long-lasting protective efficacies of CEs were associated with
the molecular size, but not the degree of modification to the methyl or hydroxypropyl group.
Biologically, long-lasting protective efficacies were significantly associated with macrophage
uptake ratios: CEs less phagocytized by macrophages were more effective. These data appear to
be consistent with the structure-activity data, which shown that the efficacies of CEs were abol-
ished by hydrophobic, but not hydrophilic, modifications. This can be explained by the find-
ings of Tabata and Ikada who reported that microspheres with hydrophobic surfaces are more
readily phagocytized than those with hydrophilic surfaces [39]. Therefore, it is presumable that
macrophages play a crucial role in the efficacies of CEs and that phagocytosis facilitates the
decomposition or excretion of CEs.
Mechanism of action of CEs
CEs are unlikely to affect the metabolism or turnover of PrPC because the expression levels of
PrPC were not modified in tissues of TC-5RW-treated mice or TC-5RW-treated culture cells.
However, CEs might directly inhibit the conversion of PrPC to PrPSc (namely prion formation)
in prion-infected animals because of the following findings: TC-5RW inhibited prion forma-
tion in the protein misfolding cyclic amplification reaction; CEs were remarkably effective
when infused into the cerebroventricular system; and radioactivity of TC-5RW was observed
in the brain parenchyma at an amount of less than 10 μg/g tissue equivalent and was elimi-
nated very slowly in the brain parenchyma at a half-life of about one year.
On the other hand, there was a gap in the CE concentration required for inhibition of
prion formation among the assay systems. CE concentration of less than 10 μg/g tissue
equivalent was needed in the mouse brain, and this concentration appeared to be similar to
that of the protein misfolding cyclic amplification reaction (~10 μg/mL), whereas it was
misfolding cyclic amplification reaction performed in the presence of TC-5RW. Representative quadruplicate
data are shown for the cyclic amplification of 263K prion performed in the presence (+) or absence (−) of TC-
5RW or hydroxypropyl methyl dextran-70 kDa (HP-M-dextran-70) at a dose of 10 μg/mL. HP-M-dextran-70
was used as a negative control. In the absence of each compound, the vehicle, water, was added to the
reaction mixture. (d) Immunoblotting of protease-resistant PrPSc in RML prion-infected N2a cells treated with
HPMCs. Signals for β-actin are shown as controls for the integrity of samples used for PrPSc detection. The
chemical property and in vivo efficacy of TC-5EW are shown in S4 Fig. (e) Immunoblotting of PrPC in
uninfected N2a cells treated with HPMCs at a dose of 1 mg/mL in duplicate. (f) Flow cytometry of cell surface
PrPC in uninfected N2a cells treated with HPMCs at a dose of 1 mg/mL. Black and blue lines indicate vehicle-
treated cells and HPMC-treated cells, respectively. The broken line peaks on the left show the respective
isotype controls.
doi:10.1371/journal.ppat.1006045.g009
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different from that of the prion-infected cells (~1 mg/mL). Because the prion strain differed
among these assay systems, the CE concentration gap might reflect the prion strain depen-
dency of CE action: significantly effective against the 263K prion, but much less effective
against the RML prion. However, it is possible that the mechanism of action of CEs differs
among the assay systems, and the possibility cannot be ruled out that other factors, such as
CE-metabolites or CE-induced host factors, are responsible for the anti-prion activities of
CEs in animals.
CE efficacy is influenced by prion disease animal models
Although CE effects were significantly observed in all prion disease animal models tested in
the present study (except for the ICR mouse model), CE effects in animals infected with
mouse-adapted prions were not as remarkable as those of animals infected with the 263K ham-
ster-adapted prion. In addition, CE effects were not necessarily remarkable in animal models
with shorter incubation periods. Thus, these findings imply that CE effects may be influenced
by the prion strain or animal genetic background.
Because no animals with an identical genetic background are available for comparison of
CE efficacies against hamster-adapted prions vs. mouse-adapted prions, it is not possible at the
present time to verify the influence associated with prion strains. Regarding the animal genetic
background, Tg7 mice have a mixed background with 129/Ola and C57BL/10 [13–15]. Thus,
the genetic background of Tg7 mice is very different from that of C57BL/6, whereas Tga20
mice have a genetic background close to C57BL/6 [22]. Accordingly, the animal genetic back-
ground might influence the effects of CEs. Although this inference remains to be elucidated,
the data of the comparison between ddY and ICR mice are suggestive of inference.
CEs as a preventive drug model
Tremendous efforts have been made to conduct clinical trials or experimental treatments of
several compounds [40–45]. However, there have been no meaningful outcomes in regard to
patient benefit. One of the reasons clinical trials commonly fail in terms of survival is supposed
to be delayed intervention. In prion-infected animals, the larger delay in intervention, the less
effective anti-prion compounds are at prolonging survival [12,21]. The most opportune time
for therapeutic intervention of prion diseases is very early in the preclinical stage because expo-
nentially accumulated amounts of the prion almost reach a plateau in the brain around the
stage of symptomatic disease [46,47].
Because the effectiveness of CEs administered after disease onset were also very limited,
despite being statistically significant, therapeutic effects are hardly expected for intervention
after disease onset. However, significantly beneficial effectiveness of CEs might be expected by
immediate post-infection or pre-exposure prophylactic intervention. Especially at peripheral
infection, a few or several injections of CEs might be sufficiently preventive to keep infected
individuals healthy for the expected lifetime. However, the safety properties of CEs remain to
be evaluated and drug availability to target tissues must be improved before the dosing regi-
men can be optimized.
In conclusion, it is not yet clear how polymers, such as CEs, peripherally administered sup-
press the disease process in the brain and extend survival. It is also unclear how CE efficacy is
influenced by prion strains or host genetic factors. These enigmas await further elucidation.
However, the findings of this study suggest that CEs may be something in daily life that modify
disease onset and could be useful for the development of preventive measures against prion
diseases.
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Materials and Methods
Ethics statement
All animal experiments were performed in accordance with protocols reviewed and approved
by the Institutional Animal Care and Use Committee of Tohoku University (approval num-
bers 20MdA-54, 21MdA-192, 22MdA-247, 2011MdA-347, 2012MdA-272, 2013MdA-194, and
2016MdA-139). The animal care and use protocols adhered to the Fundamental Guidelines
for Proper Conduct of Animal Experiment and Related Activities in Academic Research Insti-
tutions by the Ministry of Education, Culture, Sports, Science and Technology (Notice No. 71
issued on June 1, 2006), the Standards Relating to the Care and Management of Laboratory
Animals and Relief of Pain by the Ministry of the Environment (Notice No. 84 issued on
August 30, 2013), and the Act on Welfare and Management of Animals (revised on September
5, 2012) in Japan.
CEs
All HPMC compounds were kindly provided by Shin-Etsu Chemical Co., Ltd. (Tokyo,
Japan). Compound properties are listed in Fig 1a. Methyl cellulose (SM-4) was also pro-
vided by Shin-Etsu Chemical Co., Ltd. All SM-4 derivatives were synthesized from SM-4 by
Meito Sangyo Co., Ltd. (Nagoya, Japan). A chemical summary of SM-4 and its derivatives is
presented in Fig 7a.
Animal study
Tg7 mice, kindly provided by Dr. Bruce Chesebro of the Laboratory of Persistent Viral Dis-
eases of NIAID’s Rocky Mountain Laboratories (Hamilton, MT, USA), were mainly used in
the study because they have substantially shorter incubation times than Syrian hamsters when
intracerebrally infected with the hamster-adapted 263K scrapie prion [13–15]. Tg7 mice are
derived from transgenic Tg10 mice [13] and are crossed onto a mouse PrP-null background
[48]. Thus, Tg7 mice lack endogenous mouse PrPC expression but express hamster PrPC at
about 4 times the level of that expressed by wild-type mice in the brain and at a level similar to
that expressed by wild-type mice in the spleen (S11 Fig). Six- to 10-week-old male mice were
used for all experiments, unless otherwise stated. Intracerebral or intraperitoneal infection was
performed by inoculation with 20 or 100 μL, respectively, of a 1% (w/v) brain homogenate
obtained from a terminally ill 263K prion-infected hamster. In case of continuous intracereb-
roventricular infusion, continuous infusion into the cerebral third ventricle was performed
using an osmotic minipump and brain infusion kit, as previously described [49]. Mice were
monitored every day until the time of terminal disease, at which time the mice were akinetic
(with a lack of grooming behavior, coordination, and parachute reaction) or exhibited a rigid
tail, an arched back, and weight loss of approximately 10% within one week. The mice were
killed at this stage and disease was confirmed by immunoblotting and immunohistochemical
analyses of abnormal PrP deposition in the brain, as previously described [12,49]. Because it
was difficult to determine the time of symptom onset in the animal model used in this study,
survival time was defined as the time from prion infection to terminal disease.
Experiments with Syrian hamsters and other mice were performed in a similar manner, as
described above. Syrian hamsters and C57BL/6 mice were purchased from Japan SLC, Inc.
(Hamamatsu, Japan). In the case of post-infection CE administration into intraperitoneally
prion-infected hamsters, hamsters in all experimental groups were given a single subcutaneous
injection of CEs in such a manner that all intraperitoneal prion infections were performed
with animals of the same age.
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Pharmacokinetics of 14C-TC-5RW
14C-TC-5RW was synthesized by the condensation of NaOH-treated TC-5RW with 14C-
methyl iodide, and a pharmacokinetic study of 14C-TC-5RW in Tg7 mice was performed at
Sekisui Medical Co., Ltd. (Tsukuba, Japan) as follows. A designated amount of 14C-TC-5RW
in saline was subcutaneously injected into the backs of mice. After a designated interval, mice
under deep anesthesia were frozen and embedded in 4% carboxymethyl cellulose-Na. Whole-
body 30-μm-thick sections were cut with a cryomicrotome and dried. Sections accompanied
by radioactive standards were exposed to imaging plates and radioluminograms were analyzed
with a BAS2500 bio-imaging analyzer (Fuji Film, Tokyo, Japan). Considering both the stan-
dard calibration curve data and the 14C-TC-5RW specific radioactivity, radioactivity levels in
each tissue or fluid sample were calculated from the radioluminograms. Elimination half-life
was calculated using the following formula: elimination half-life (days) = –ln2/β, where β is the
slope obtained from the simple linear regression of the natural logarithm of radioactivity levels
on post-injection days. To measure the molecular sizes of 14C-TC-5RW residues in tissues, tis-
sue samples were homogenized with five volumes of 0.1 N NaOH on ice, and the supernatants
after centrifugation at 12,000×g were subjected to GPC analysis. Samples were separated on an
OHpak SB-804 HQ column (Showa Denko, Tokyo, Japan) and eluted with 0.1 M NaCl at 1
mL/min and 35˚C. Each 0.5-min fraction was mixed with the scintillation cocktail and radio-
activity was assayed by liquid scintillation counting.
Macrophage uptake analysis
Fluorescein-labeled HPMCs were produced as follows. HPMC in dimethylformamide (0.3 g/
30 mL) was mixed with fluorescein-5-carbonyl azide diacetate (1.5 mg). The mixture was
purged with N2 gas and agitated at 90˚C for 3 h. Labeled HPMC was recovered and then puri-
fied using repeated precipitation–solubilization steps. Residual solids were dissolved in
NaHCO3 solution (100 mM, pH 8.0) at room temperature for 8 h to remove the acetyl-protect-
ing groups and subsequently dialyzed against deionized water. The solution was filtered
through a 0.45-μm pore size filter (EMD Millipore, Billerica, MA, USA) and then lyophilized.
Fluorescein-labeled HPMCs showed no fluorescence signals in the low-molecular-weight frac-
tions on a GPC instrument equipped with a fluorescence detector (column, OHpak SB-804
HQ; detection, excitation at 494 nm and recording at 520 nm). Peritoneal macrophages were
obtained from Tg7 mice by conventional thioglycollate induction. Cells (3 × 105) were incu-
bated with fluorescein-labeled HPMC (1 mg/mL) in culture medium for 1 day and then rinsed
twice and lysed in a lysis buffer (0.5% sodium deoxycholate, 0.5% Nonidet P-40, phosphate-
buffered saline (PBS), pH 7.4). The amount of fluorescein-labeled HPMC in the cell lysate was
determined by GPC analysis.
PrP expression analysis
Brains were homogenized in two volumes of TN buffer (50 mM Tris HCl, 0.1 M NaCl, pH 7.5)
supplemented with a protease inhibitor cocktail. Spleens were homogenized and sonicated in
13 volumes of TN buffer supplemented with 0.5% sodium deoxycholate, 0.5% Nonidet P-40,
and the protease inhibitor cocktail. After low-speed centrifugation, aliquots of supernatant
containing the same protein amount were analyzed for PrPC protein levels by immunoblotting
with the anti-PrP monoclonal antibody 3F4 (BioLegend, Inc., San Diego, CA, USA), as previ-
ously described [19]. To analyze PrP mRNA expression, the brains and spleens of Tg7 mice
were lysed using an RNA extraction reagent. Total RNA was extracted and cDNA was synthe-
sized using a first-strand cDNA synthesis kit (Takara Bio, Inc., Kyoto, Japan). The PrP mRNA
level was measured by real-time polymerase chain reaction, as previously described [49].
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Protein misfolding cyclic amplification
According to a previously described method [50], a reaction mixture containing 0.1% 263K
prion-infected hamster brain homogenate and 10% normal hamster brain homogenate under-
went 96 cycles of sonication and incubation with an automatic cross-ultrasonic apparatus
(ELESTEIN 070-GOTW; Elekon Science Corp., Chiba, Japan). TC-5RW or hydroxypropyl
methyl dextran (70 kDa) was added to the reaction mixture before starting the reactions at
concentrations ranging 10 μg/mL to 1 mg/mL. After the reactions, the samples were digested
with 100 μg/mL of proteinase K at 37˚C for 1 h and levels of protease-resistant PrPSc were
detected by immunoblotting with 3F4.
Analysis in prion-infected cells
Mouse neuroblastoma cells either uninfected (N2a cells) or persistently infected with the RML
prion (ScN2a cells [24]) were kindly provided by Dr. Byron Caughey of the Laboratory of Per-
sistent Viral Diseases of NIAID’s Rocky Mountain Laboratories (Hamilton, MT, USA) and
used as previously described [21,51,52]. Briefly, cells were cultured in the presence of test com-
pounds for 3 days. Cells grown to confluency were washed with PBS and lysed with lysis buffer
(0.5% sodium deoxycholate, 0.5% Nonidet P-40, PBS, pH 7.4). For the detection of PrPSc, cell
lysate was treated with 10 μg/mL of proteinase K at 37˚C for 30 min and subsequently with 1
mM phenylmethylsulfonyl fluoride. Then, PrPSc were precipitated by centrifugation at 10,000
× g and suspended in a sample loading buffer. To detect PrPC and β-actin, cell lysate was used
without further treatments and mixed with a concentrated loading buffer. Immunoblotting
analysis was performed using the anti-PrP monoclonal antibody SAF83 (SPI-Bio, Massy,
France) and anti-β-actin monoclonal antibody, as described previously [49]
The cell surface of PrPC was analyzed by flow cytometry, as described in previous reports
[21,49,52]. Briefly, N2a cells incubated in the presence of test compounds for 3 days were dis-
persed using 0.1% collagenase and washed with ice-cold 0.5% fetal calf serum in PBS. Then,
the cells were immunoreacted with SAF83 or isotype control IgG1 for 30 min on ice, and sub-
sequently with goat F(ab’)2 fragment anti-mouse IgG (H+L)-FITC (Beckman Coulter, Inc.,
Brea, CA, USA) for 30 min on ice. Then, the cells were analyzed using an EPICS XL-ADC flow
cytometer (Beckman Coulter, Inc.).
Statistical analysis
Survival rates were calculated using the Kaplan–Meier method and significance was evaluated
using the log-rank method. Statistical linear correlations were evaluated by the Pearson’s cor-
relation coefficient. All analyses were performed using Excel Toukei, a statistical analysis soft-
ware (SSRI Co., Ltd., Tokyo, Japan).
Supporting Information
S1 Fig. Efficacy of low-molecular-size CEs. Survival analysis of Tg7 mice intracerebrally
infected with the 263K prion and treated with hexamer CEs via a 4-week continuous intracer-
ebroventricular infusion (150 μg/day) from 2 dpi was performed. Hexamer CEs were synthe-
sized from hexacellulose by Meito Sangyo Co., Ltd. (Nagoya, Japan). M-6Cr had an O-CH3
content of 1.81 mol/AGU and a reduced OH terminus, whereas HPM-6Cr had an O-CH2CH
(OH)CH3 content of 0.27 mol/AGU in addition to M-6Cr chemical properties.
(TIF)
S2 Fig. Dose response of TC-5RW. TC-5RW dose response was analyzed in Tg7 mice intrace-
rebrally infected with the 263K prion via a single subcutaneous injection at 0 or 7 dpi or a
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4-week continuous intracerebroventricular infusion from 8 dpi. Median and quartiles are
shown (n = 5 or 6 for each time point).
(TIF)
S3 Fig. Effect of changes in CE modification. Survival analysis was performed in Tg7 mice
intracerebrally infected with the 263K prion and treated 3 days pre-infection with a single sub-
cutaneous injection (2 g/kg body weight) of HPMCs with similar viscosities but different mod-
ifications (60SH-4K vs. 90SH-4K and HPMC602 vs. HPMC902).
(TIF)
S4 Fig. Effect of activated carbon treatment on CE efficacy. Survival analysis was performed
as described in S3 Fig using either activated carbon-treated HPMCs or untreated HPMCs
(TC-5RW vs. TC-5R and TC-5EW vs. TC-5E).
(TIF)
S5 Fig. CE efficacy independent of age and sex of animals. Box plots of survival periods in
old (43–53 months) and young (6–10 months) male (M) and female (F) mice are shown. Tg7
mice were treated with a single intraperitoneal injection (1 g/kg body weight) 1 day before
intracerebral infection with the 263K prion. No significant difference was observed among
TC-5RW-treated groups (n = 5 or 6 for each group) or vehicle-treated groups (n = 6 for each
group); log-rank test.
(TIF)
S6 Fig. Prophylactic effects of CEs via other administration routes. (a) Survival analysis was
performed in Tg7 mice intracerebrally infected with the 263K prion and treated with TC-5RW
via a single intraperitoneal infusion (1 g/kg body weight) immediately after infection or via a
single intravenous injection (0.3 g/kg body weight) 6 h pre-infection. (b) Survival analysis was
performed in Tg7 mice intracerebrally infected with the 263K prion and treated with a 15%
TC-5RW-containing diet from 9 days pre-infection to akinetic terminal disease.
(TIF)
S7 Fig. Pretreatment efficacy in intraperitoneally infected hamsters. Survival analysis was
performed in Syrian hamsters intraperitoneally infected with the 263K prion and treated with
HPMCs via a single subcutaneous injection (4 g/kg body weight) at 0 or 13 months before
infection.
(TIF)
S8 Fig. Pharmacokinetics of subcutaneously injected 14C-TC-5RW; absorption and excre-
tion. (a) Blood 14C-TC-5RW radioactivity levels in Tg7 mice that received a single subcutane-
ous injection of 14C-TC-5RW at 2 g/kg body weight. The mean and standard deviation are
shown from technical triplicates at 3 or 6 months (n = 1) and from biological triplicates at
other time points (n = 3). (b) Kinetics of 14C-TC-5RW radioactivity excretion by Tg7 mice
that received a single subcutaneous injection of 14C-TC-5RW at 0.1 g/kg body weight. Total
excretion radioactivity levels were determined from whole-body residual radioactivity levels.
The mean and standard deviation are shown (n = 3). (c) 14C-TC-5RW molecular size profiles
in the plasma, urine, and feces of Tg7 mice described in (b). GPC profiles of radioactivity were
analyzed in plasma and excreta within 2 weeks and 3 days, respectively, of post-subcutaneous
injection of 14C-TC-5RW (n = 1). RT, peak retention time; psi, post-subcutaneous injection.
Methods: A designated amount of 14C-TC-5RW in saline was subcutaneously injected into the
backs of mice. Blood or excreta samples were collected from the mice at designated time
points. Urine and feces were collected in metabolic cages and expired CO2 was captured in
20% ethanolamine solution. Feces were dissolved with a scintillation solubilizer. The whole
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body was solubilized in heated 0.5 N NaOH/5% toluene solution to assay whole-body residual
radioactivity. Portions of samples were mixed with a scintillation cocktail and radioactivity
was assayed by liquid scintillation counting. GPC analysis was performed in a similar manner
as described in the Materials and Methods section.
(TIF)
S9 Fig. CE efficacies in other prion disease animal models. (a) Survival analysis of C57BL/6
mice intracerebrally infected with the 22L prion and treated with a single subcutaneous injec-
tion of CEs at 2 g/kg body weight 1 day before infection.(b) Survival analysis of Tga20 mice
intracerebrally infected with the RML prion and treated with a single subcutaneous injection
of CEs at 4 g/kg body weight immediately after infection. Tga20 mice overexpressing mouse
PrPC [22] were kindly provided by Dr. Charles Weissmann of the Scripps Research Institute
(La Jolla, CA, USA).
(TIF)
S10 Fig. Comparison of CE efficacy in two mouse strains. Survival analysis of ddY and ICR
mice intracerebrally infected with the RML prion and treated with a single subcutaneous injec-
tion of TC-5RW (2.5 g/kg body weight) 1 day before infection. These mice were purchased
from Japan SLC, Inc. (Hamamatsu, Japan).
(TIF)
S11 Fig. PrPC expression in Tg7 mice. (a) PrPC levels in the brain from Tg7 and C57BL/6
(B6) mice. Brain homogenates containing 5 μg protein were analyzed by immunoblotting with
SAF83 antibody (n = 4 for each mouse strain). Molecular size markers on the right indicate
sizes in kDa. (b) Quantitative comparison of PrPC levels in the brain between Tg7 and B6
mice. Two of the Tg7 brain samples in (a) were diluted and the PrPC levels were compared
with those of undiluted B6 brain samples by immunoblotting. A plot of relative signal intensi-
ties for Tg7 samples (% of B6) is shown against dilution ratios; the mean and standard devia-
tion were obtained from technical triplicate analysis (n = 2 for each mouse strain). (c) PrPC
levels in the spleen from Tg7 and B6 mice. Spleen homogenates containing 10 μg protein were
analyzed by immunoblotting as described in (a) (n = 4 for each mouse strain). The mean and
standard deviation of signal intensities are shown. NS not significant; t-test.
(TIF)
S1 Table. Other tested polysaccharide ethers. Survival analyses were performed in 263K
prion-infected Tg7 mice treated with a single dose of each sample at a designated timing, as
described in the Materials and Methods section. Dextran and dextrin were provided by Meito
Sangyo (Nagoya, Japan) and pullulan by Hayashibara (Okayama, Japan). Hydroxypropyl
methyl ethers of these compounds were synthesized by Meito Sangyo. Other compounds were
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